Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

1.035 +0.035 (+3.50%)
Streaming Delayed Price Updated: 10:05 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Skye Bioscience, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Top stock movements in today's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models ↗
Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential. 
Via Benzinga
News headline image
Tuesday's session: top gainers and losers ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Tuesday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
News headline image
Crude Oil Moves Lower; Citigroup Posts Upbeat Results ↗
 
Via Benzinga
News headline image
Nasdaq Surges 100 Points; Bank of America Earnings Top Views ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tuesday's session: top gainers and losers ↗
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Top Picks For 2025: Skye Bioscience ↗
Skye Bioscience is developing a peripheral restricted CB1 antibody to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects.... 
Via Talk Markets
Topics Stocks / Equities
News headline image
MarketBeat Week in Review – 10/7 - 10/11
Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s. 
Via MarketBeat
News headline image
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore
Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure. 
Via MarketBeat
Topics Bankruptcy
News headline image
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players ↗
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus... 
Via Benzinga
News headline image
US Stocks Edge Lower; FedEx Earnings Miss Views ↗
 
Via Benzinga
Topics Earnings
News headline image
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
From Beacon Biosignals
Via GlobeNewswire
News headline image
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI ↗
Although fraught with risk, these biotech exposures bring enormous upside potential. 
Via Talk Markets
News headline image
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet ↗
The company is focusing on obesity treatment after its glaucoma drug failed. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher? ↗
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game. 
Via InvestorPlace
News headline image
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.